# To Demonstrate the Relative Bioavailability of Bupropion HCI 300 mg Extended-Release Tablets Under Fasting Conditions

> **NCT00861939** · PHASE1 · COMPLETED · sponsor: **Sandoz** · enrollment: 28 (actual)

## Conditions studied

- Depression

## Interventions

- **DRUG:** Bupropion HCI 300 mg Extended-Release Tablets EON
- **DRUG:** WELLBUTRIN XL 300 mg Extended-Release Tablets GlaxoSmithKline

## Key facts

- **NCT ID:** NCT00861939
- **Lead sponsor:** Sandoz
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** 2004-04
- **Final completion:** 2004-04
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2017-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00861939

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00861939, "To Demonstrate the Relative Bioavailability of Bupropion HCI 300 mg Extended-Release Tablets Under Fasting Conditions". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT00861939. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*